Equity to Asset ratio is calculated as total stockholders equity divided by total asset. DBV Technologies's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $140.19 Mil. DBV Technologies's Total Assets for the quarter that ended in Dec. 2023 was $182.99 Mil.
The historical rank and industry rank for DBV Technologies's Equity-to-Asset or its related term are showing as below:
DBVT'
s Equity-to-Asset Range Over the Past 10 Years
Min: 0.68 Med: 0.76 Max: 0.94
Current: 0.77
During the past 13 years, the highest Equity to Asset Ratio of DBV Technologies was 0.94. The lowest was 0.68. And the median was 0.76.
DBVT's Equity-to-Asset is ranked better than 63.58% of 1565
companies
in the Biotechnology industry
Industry Median: 0.67
vs DBVT: 0.77
DBV Technologies Equity-to-Asset Historical Data
The historical data trend for DBV Technologies's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of DBV Technologies's Equity-to-Asset
For the Biotechnology subindustry, DBV Technologies's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
DBV Technologies's Equity-to-Asset Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, DBV Technologies's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where DBV Technologies's Equity-to-Asset falls into.
DBV Technologies Equity-to-Asset Calculation
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
DBV Technologies's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
DBV Technologies Equity-to-Asset Related Terms
Thank you for viewing the detailed overview of DBV Technologies's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.
DBV Technologies (DBV Technologies) Business Description
DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Viaskin targets specific antigen-presenting immune cells in the skin, called Langerhans cells, that capture the antigen and migrate to the lymph node in order to activate the immune system without passage of the antigen into the bloodstream, minimizing systemic exposure in the body. Its main product candidate is Viaskin Peanut for the treatment of peanut-allergic patients.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
DBVT has been successfully added to your 